Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models

References

• Torchilin VP. Drug targeting. Eur J Pharm Sci 2000; 11:Suppl 2 S81 - 91; http://dx.doi.org/10.1016/S0928-0987(00)00166-4; PMID: 11033430
   PubMed Web of Science ®Google Scholar
• Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994; 263:1600 - 3; http://dx.doi.org/10.1126/science.8128245; PMID: 8128245
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 2007; 9:E128 - 47; http://dx.doi.org/10.1208/aapsj0902015; PMID: 17614355
   PubMed Web of Science ®Google Scholar
• Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S, Paraghamian A, Ben-David Y, Kerbel RS. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 2005; 65:7045 - 51; http://dx.doi.org/10.1158/0008-5472.CAN-05-0765; PMID: 16103050
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Pastan I. Mechanisms of Drug-Resistance in Cancer-Therapy. Eur J Pharmacol 1990; 183:17 - 8; http://dx.doi.org/10.1016/0014-2999(90)91262-A
   Web of Science ®Google Scholar
• Filipits M. Mechanisms of cancer: multidrug resistance. Drug Discov Today Dis Mech 2004; 1:229 - 34; http://dx.doi.org/10.1016/j.ddmec.2004.10.001
   Google Scholar
• Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005; 204:216 - 37; http://dx.doi.org/10.1016/j.taap.2004.10.012; PMID: 15845415
   PubMed Web of Science ®Google Scholar
• Krishna R, Mayer LD. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res 1997; 57:5246 - 53; PMID: 9393743
   PubMed Web of Science ®Google Scholar
• Gaber MH. Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia. J Biochem Mol Biol Biophys 2002; 6:309 - 14; http://dx.doi.org/10.1080/10258140290033066; PMID: 12385965
   PubMedGoogle Scholar
• Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat 2003; 6:271 - 9; http://dx.doi.org/10.1016/S1368-7646(03)00082-7; PMID: 14643297
   PubMed Web of Science ®Google Scholar
• Barraud L, Merle P, Soma E, Lefrançois L, Guerret S, Chevallier M, Dubernet C, Couvreur P, Trépo C, Vitvitski L. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol 2005; 42:736 - 43; http://dx.doi.org/10.1016/j.jhep.2004.12.035; PMID: 15826724
   PubMed Web of Science ®Google Scholar
• van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM. Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems. AAPS J 2010; 12:171 - 80; http://dx.doi.org/10.1208/s12248-010-9174-4; PMID: 20143195
   PubMed Web of Science ®Google Scholar
• Kopecek J, Kopecková P, Minko T, Lu ZR, Peterson CM. Water soluble polymers in tumor targeted delivery. J Control Release 2001; 74:147 - 58; http://dx.doi.org/10.1016/S0168-3659(01)00330-3; PMID: 11489491
   PubMed Web of Science ®Google Scholar
• Kang DI, Kang HK, Gwak HS, Han HK, Lim SJ. Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cells. Drug Deliv 2009; 16:261 - 7; http://dx.doi.org/10.1080/10717540902937562; PMID: 19538007
   PubMed Web of Science ®Google Scholar
• Patel NR, Pattni BS, Abouzeid AH, Torchilin VP. Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev 2013; Forthcoming http://dx.doi.org/10.1016/j.addr.2013.08.004
   PubMed Web of Science ®Google Scholar
• Liang JF, Yang VC. Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity. Bioorg Med Chem Lett 2005; 15:5071 - 5; http://dx.doi.org/10.1016/j.bmcl.2005.07.087; PMID: 16168650
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4:145 - 60; http://dx.doi.org/10.1038/nrd1632; PMID: 15688077
   PubMed Web of Science ®Google Scholar
• Maeda H, Matsumura Y, Kato H. Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer. J Biol Chem 1988; 263:16051 - 4; PMID: 3182782
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65:271 - 84; http://dx.doi.org/10.1016/S0168-3659(99)00248-5; PMID: 10699287
   PubMed Web of Science ®Google Scholar
• Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 2001; 74:47 - 61; http://dx.doi.org/10.1016/S0168-3659(01)00309-1; PMID: 11489482
   PubMed Web of Science ®Google Scholar
• Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990; 9:253 - 66; http://dx.doi.org/10.1007/BF00046364; PMID: 2292138
   PubMed Web of Science ®Google Scholar
• Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55:3752 - 6; PMID: 7641188
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Omelyanenko VG, Papisov MI, Bogdanov AA Jr., Trubetskoy VS, Herron JN, Gentry CA. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta 1994; 1195:11 - 20; http://dx.doi.org/10.1016/0005-2736(94)90003-5; PMID: 7918551
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Trubetskoy VS. Which polymers can make nanoparticulate drug carriers long-circulating?. Adv Drug Deliv Rev 1995 a; 16:141 - 55; http://dx.doi.org/10.1016/0169-409X(95)00022-Y
   Web of Science ®Google Scholar
• Torchilin VP. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm 2009; 71:431 - 44; http://dx.doi.org/10.1016/j.ejpb.2008.09.026; PMID: 18977297
   PubMed Web of Science ®Google Scholar
• Koshkaryev A, Sawant R, Deshpande M, Torchilin V. Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv Drug Deliv Rev 2013; 65:24 - 35; http://dx.doi.org/10.1016/j.addr.2012.08.009; PMID: 22964425
   PubMed Web of Science ®Google Scholar
• Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release 2004; 100:135 - 44; http://dx.doi.org/10.1016/j.jconrel.2004.08.007; PMID: 15491817
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Levchenko TS, Lukyanov AN, Khaw BA, Klibanov AL, Rammohan R, Samokhin GP, Whiteman KR. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim Biophys Acta 2001; 1511:397 - 411; http://dx.doi.org/10.1016/S0005-2728(01)00165-7; PMID: 11286983
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci U S A 2003; 100:6039 - 44; http://dx.doi.org/10.1073/pnas.0931428100; PMID: 12716967
   PubMed Web of Science ®Google Scholar
• MacKay JA, Li W, Huang Z, Dy EE, Huynh G, Tihan T, Collins R, Deen DF, Szoka FC Jr.. HIV TAT peptide modifies the distribution of DNA nanolipoparticles following convection-enhanced delivery. Mol Ther 2008; 16:893 - 900; http://dx.doi.org/10.1038/mt.2008.36; PMID: 18388927
   PubMed Web of Science ®Google Scholar
• Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55:1189 - 93; http://dx.doi.org/10.1016/0092-8674(88)90263-2; PMID: 2849510
   PubMed Web of Science ®Google Scholar
• Elmquist A, Langel U. In vitro uptake and stability study of pVEC and its all-D analog. Biol Chem 2003; 384:387 - 93; http://dx.doi.org/10.1515/BC.2003.044; PMID: 12715889
   PubMed Web of Science ®Google Scholar
• Koren E, Torchilin VP. Cell-penetrating peptides: breaking through to the other side. Trends Mol Med 2012; 18:385 - 93; http://dx.doi.org/10.1016/j.molmed.2012.04.012; PMID: 22682515
   PubMed Web of Science ®Google Scholar
• Koren E, Apte A, Sawant RR, Grunwald J, Torchilin VP. Cell-penetrating TAT peptide in drug delivery systems: proteolytic stability requirements. Drug Deliv 2011; 18:377 - 84; http://dx.doi.org/10.3109/10717544.2011.567310; PMID: 21438724
   PubMed Web of Science ®Google Scholar
• Levchenko TS, Rammohan R, Volodina N, Torchilin VP. Tat peptide-mediated intracellular delivery of liposomes. Methods Enzymol 2003; 372:339 - 49; http://dx.doi.org/10.1016/S0076-6879(03)72019-9; PMID: 14610822
   PubMed Web of Science ®Google Scholar
• Sawant RR, Torchilin VP. Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo. Int J Pharm 2009; 374:114 - 8; http://dx.doi.org/10.1016/j.ijpharm.2009.02.022; PMID: 19446767
   PubMed Web of Science ®Google Scholar
• Gupta B, Levchenko TS, Torchilin VP. TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice. Oncol Res 2007; 16:351 - 9; PMID: 17913043
   PubMed Web of Science ®Google Scholar
• Grunwald J, Rejtar T, Sawant R, Wang Z, Torchilin VP. TAT peptide and its conjugates: proteolytic stability. Bioconjug Chem 2009; 20:1531 - 7; http://dx.doi.org/10.1021/bc900081e; PMID: 19601640
   PubMed Web of Science ®Google Scholar
• Kale AA, Torchilin VP. Enhanced transfection of tumor cells in vivo using “Smart” pH-sensitive TAT-modified pegylated liposomes. J Drug Target 2007; 15:538 - 45; http://dx.doi.org/10.1080/10611860701498203; PMID: 17671900
   PubMed Web of Science ®Google Scholar
• Kale AA, Torchilin VP. Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates. Bioconjug Chem 2007; 18:363 - 70; http://dx.doi.org/10.1021/bc060228x; PMID: 17309227
   PubMed Web of Science ®Google Scholar
• Sawant RM, Hurley JP, Salmaso S, Kale A, Tolcheva E, Levchenko TS, Torchilin VP. “SMART” drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem 2006; 17:943 - 9; http://dx.doi.org/10.1021/bc060080h; PMID: 16848401
   PubMed Web of Science ®Google Scholar
• Koren E, Apte A, Jani A, Torchilin VP. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J Control Release 2012; 160:264 - 73; http://dx.doi.org/10.1016/j.jconrel.2011.12.002; PMID: 22182771
   PubMed Web of Science ®Google Scholar
• Zhu L, Torchilin VP. Stimulus-responsive nanopreparations for tumor targeting. Integr Biol (Camb) 2013; 5:96 - 107; http://dx.doi.org/10.1039/c2ib20135f; PMID: 22869005
   PubMed Web of Science ®Google Scholar
• Allen TM, Sapra P, Moase E. Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell Mol Biol Lett 2002; 7:889 - 94; PMID: 12378272
   PubMed Web of Science ®Google Scholar
• Niesner UHC, Halin C, Lozzi L, Günthert M, Neri P, Wunderli-Allenspach H, Zardi L, Neri D. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem 2002; 13:729 - 36; http://dx.doi.org/10.1021/bc025517+; PMID: 12121127
   PubMed Web of Science ®Google Scholar
• Tréhin R, Nielsen HM, Jahnke HG, Krauss U, Beck-Sickinger AG, Merkle HP. Metabolic cleavage of cell-penetrating peptides in contact with epithelial models: human calcitonin (hCT)-derived peptides, Tat(47-57) and penetratin(43-58). Biochem J 2004; 382:945 - 56; http://dx.doi.org/10.1042/BJ20040238; PMID: 15193145
   PubMed Web of Science ®Google Scholar
• Foerg C, Weller KM, Rechsteiner H, Nielsen HM, Fernández-Carneado J, Brunisholz R, Giralt E, Merkle HP. Metabolic cleavage and translocation efficiency of selected cell penetrating peptides: a comparative study with epithelial cell cultures. AAPS J 2008; 10:349 - 59; http://dx.doi.org/10.1208/s12248-008-9029-4; PMID: 18587651
   PubMed Web of Science ®Google Scholar
• Lee HJ, Pardridge WM. Pharmacokinetics and delivery of tat and tat-protein conjugates to tissues in vivo. Bioconjug Chem 2001; 12:995 - 9; http://dx.doi.org/10.1021/bc0155061; PMID: 11716691
   PubMed Web of Science ®Google Scholar
• Allen T, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly (ethylene glycol) show prolonged circulation half-lives in vivo. Biochimica et Biophysica Acta (BBA)-. Biomembranes 1991; 1066:29 - 36; http://dx.doi.org/10.1016/0005-2736(91)90246-5
   Google Scholar
• Khalid MN, Simard P, Hoarau D, Dragomir A, Leroux J-C. Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors. Pharm Res 2006; 23:752 - 8; http://dx.doi.org/10.1007/s11095-006-9662-5; PMID: 16550475
   PubMed Web of Science ®Google Scholar
• Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, Montrose MH, Beck WT, Erickson LC. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther 2008; 324:95 - 102; http://dx.doi.org/10.1124/jpet.107.127704; PMID: 17947497
   PubMed Web of Science ®Google Scholar
• Elbayoumi T. TVP. Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice. Mol Pharm 2008; 6:246 - 54; http://dx.doi.org/10.1021/mp8001528
   Web of Science ®Google Scholar
• Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci U S A 2001; 98:8786 - 91; http://dx.doi.org/10.1073/pnas.151247498; PMID: 11438707
   PubMed Web of Science ®Google Scholar
• Elbayoumi T, Torchilin VP. Tumor-targeted immuno-liposomes for delivery of therapeutics and diagnostics. Pharmaceutical Engineering 2006; 26:1 - 6
   Google Scholar
• Devalapally HDZ, Duan Z, Seiden MV, Amiji MM. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin Cancer Res 2008; 14:3193 - 203; http://dx.doi.org/10.1158/1078-0432.CCR-07-4973; PMID: 18483388
   PubMed Web of Science ®Google Scholar
• ElBayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res 2009; 15:1973 - 80; http://dx.doi.org/10.1158/1078-0432.CCR-08-2392; PMID: 19276264
   PubMed Web of Science ®Google Scholar